



HIS | B Yes
Slatea

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Jean-Luc Balligand et al.

Group Art Unit: TBA

Serial No.: TBA

Examiner: TBA

Filed: February 11, 2002

For: NOVEL PHARMACEUTICAL COMPOSITIONS FOR MODULATING ANGIOGENESIS

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Prior to initial examination, please amend the above-identified application as follows:

IN THE CLAIMS:

Please amend the claims as follows:

3. (Amended) A compound according to claim 1 for use as a medicament for the modulation of angiogenesis, wherein said compound modulates intracellular free cholesterol by acting on cholesterol synthesis, cholesterol metabolism, cholesterol influx or cholesterol efflux.

4. (Amended) A compound according to claim 1 for use as a medicament for the modulation of angiogenesis, wherein said compound influences cholesterol metabolism and decreases caveolin-1 abundance and is chosen from the group comprising HMGCoA reductase inhibitors or a pharmacologically acceptable derivative thereof.

7 (Amended) A compound according to claim 1 for use as a medicament for the

pharmacologically acceptable derivative thereof.